Cargando…
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
BACKGROUND: BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-1...
Autores principales: | Thomas, Stephen J., Moreira, Edson D., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Perez, John L., Pérez Marc, Gonzalo, Polack, Fernando P., Zerbini, Cristiano, Bailey, Ruth, Swanson, Kena A., Xu, Xia, Roychoudhury, Satrajit, Koury, Kenneth, Bouguermouh, Salim, Kalina, Warren V., Cooper, David, Frenck, Robert W., Hammitt, Laura L., Türeci, Özlem, Nell, Haylene, Schaefer, Axel, Ünal, Serhat, Yang, Qi, Liberator, Paul, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Gruber, William C., Jansen, Kathrin U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461570/ https://www.ncbi.nlm.nih.gov/pubmed/34525277 http://dx.doi.org/10.1056/NEJMoa2110345 |
Ejemplares similares
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020) -
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021) -
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022) -
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021) -
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
por: Walsh, Edward E., et al.
Publicado: (2020)